Gould Gregory A purchased $5K of ACON

Gould Gregory A (CFO) purchased 3,388 shares of Aclarion, Inc. (ACON) at $1.44 on 2026-11-19.

Original reporting
SEC EDGAR · Gould Gregory A
Published Nov 20, 2026, 12:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 20, 2026, 12:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ACON
Bullish
medium confidence
Mentioned
$ACON
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ACONBullishLow
01

Why it matters

The filing provides a fresh, primary source of insider activity, but the transaction size is small, limiting market impact.

02

Market read

A minor insider buy that may slightly buoy sentiment but unlikely to move the stock materially.

03

What to watch

Potential upcoming dilution or corporate actions could offset any positive perception.

Relevance 4/10Novelty 4/10Timing: today

Background

SEC Form 4 filing discloses an insider purchase by Aclarion's CFO.

Company-level read

Ticker impact

$ACONBullishMedium confidence
Context

CFO Gregory Gould purchased 3,388 ACON shares at $1.44 each, a $4,879 buy on 2026-11-19.

Expected impact

likely slight upward pressure as market views CFO confidence

Evidence & confidence

The transaction size is modest but represents a buy by a senior officer, which can be interpreted as a positive signal.

Market effects

Minimal impact on the broader technology sector.

Limited to U.S. investors tracking ACON.

None

Counterpoint

The purchase may be routine compensation rather than a confidence signal.

Key entities

  • Aclarion, Inc.

    US-listed technology firm (ticker ACON).

  • Gregory A. Gould

    Chief Financial Officer of Aclarion.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ACONMedAI 8/10

Aclarion Updates CLARITY Enrollment Criteria, Keeps Trial Timeline On Track

Aclarion (ACON) revised its CLARITY trial enrollment criteria to expand the patient pool and accelerate enrollment, while maintaining scientific rigor. The changes were approved by most trial sites and are expected to improve enrollment consistency and real-world applicability. The company anticipates providing an enrollment update by year-end 2026, with the trial timeline remaining unchanged. ACON's stock closed at $2.35, up 2.40%.

$ACONMed

Aclarion Partners with PRIA Healthcare to Advance Reimbursement and Commercial Adoption of Its AI

Aclarion (Nasdaq: ACON) said it launched a U.S. Market Access Program with PRIA Healthcare to advance reimbursement and commercial adoption of its AI platform Nociscan for chronic low back pain. PRIA will support payer engagement, prior authorization and appeals. Aclarion cited UK payer approvals from three of four major private insurers as a basis for U.S. coverage discussions.

$ACONMedAI 8/10

Aclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence Generation

Aclarion (Nasdaq: ACON) said it has agreed with the Institute of Neuro Innovation in Los Angeles to expand availability of its Nociscan platform. The INI team led by neurosurgeon Amir Vokshoor will generate real-world evidence comparing Nociscan’s lumbar disc chemical biomarker data with bone metabolic information from SPECT-CT to support treatment decisions for chronic low back pain.